Lung Cancer

Closing insights into managing EGFR-mutant NSCLC, from evolving treatment options and sequencing strategies to addressing unmet needs and the importance of comprehensive genomic testing.

Dr Sai-Hong Ou discusses the future of treatment for non-small cell lung cancer with EGFR exon 20 insertion mutations, highlighting the complexity of these mutations and the need for precision treatments.

Unmet needs in EGFR exon 20 insertion lung cancer, emphasizing the importance of early identification, selectivity against wild type EGFR, CNS activity, and mechanisms of resistance.

Drs Misako Nagasaka, Sai-Hong Ou, Janellen Smith discuss the management of adverse events, such as infusion reactions and rash, associated with amivantamab treatment for patients with EGFR exon 20 insertion mutations.

Investigators are assessing BI 764532 in extensive-stage small cell lung cancer and other neuroendocrine carcinoma as part of the phase 2 DAREON-5 study.

Experts discuss the rapidly evolving treatment landscape for EGFR exon 20 insertion lung cancer, highlighting recent advancements in therapies, clinical trial results, and the quest for first-line treatment options, providing valuable insights into managing this unique patient population.

Sai-Hong Ou, MD, PhD, and Janellen Smith, MD, discuss the management of a patient with non-small cell lung cancer and an EGFR exon 20 insertion mutation who experienced a rash while on treatment with amivantamab; they highlight the importance of continuous treatment and potential considerations for this patient group.

Sai-Hong Ou, MD, PhD, discusses the challenging management of patients EGFR-mutant non-small cell lung cancer who develop resistance to EGFR tyrosine kinase inhibitors, emphasizing the importance of understanding the resistance mechanism to tailor treatment.

Learn about the latest developments in the treatment of lung cancer, focusing on EGFR mutations, antibody-drug conjugates (ADCs), targeted therapies, and biomarker-driven approaches to improve patient outcomes in various stages of the disease.

Drs Janellen Smith and Misako Nagasaka discuss dermatological adverse events in patients with non-small cell lung cancer associated with EGFR tyrosine kinase inhibitors, offering advice on prevention, treatment, and when to involve a dermatologist.

Shared insight into the complexities in treating EGFR mutant lung cancer during the second-line therapy phase, including safety profiles of different treatment regimens, managing toxicities, and ongoing research to improve patient outcomes.

Dr Sai-Hong Ou and Dr Misako Nagasaka discuss the treatment strategies for EGFR-mutant non-small cell lung cancer, emphasizing the importance of individualized decision making and a multidisciplinary approach.

Experts consider the influence of combination therapies on EGFR-mutant lung cancer treatment, including the impact on central nervous system (CNS) response, challenges in CNS metastases management, and the potential alternatives to whole-brain radiation.

Explore significant updates in the field of EGFR-mutant lung cancer treatment, focusing on the introduction of combination therapy in the first-line setting, including the FLAURA2., MARIPOSA, and RAMOSE trials, offering improved progression-free survival and potential implications for patient care.

Sai-Hong Ou, MD, PhD, discusses the rapidly evolving landscape of first-line therapy for sensitizing EGFR mutant non-small cell lung cancer, including potential combination therapies and the introduction of new treatment options, such as antibody drug conjugates.

Dr Sai-Hong Ou and Dr Janellen Smith discuss the case of a 59-year-old patient with non-small cell lung cancer and an EGFR mutation who experienced severe diarrhea and acne form rash while on osimertinib, providing insights into managing these treatment-related side effects.

Early CT screening leads to a 20-year lung cancer survival rate of 81%.

Dr Sai-Hong Ou highlights the significance of next-generation sequencing for detecting EGFR mutations in patients with non-small cell lung cancer and the potential for adjuvant testing regardless of disease stage.

In this program, Sai-Hong Ou, MD, PhD, discusses biomarker testing for precision medicine in non-small cell lung cancer, emphasizing the importance of both tissue and blood-based genotyping, and the need for a complementary approach due to potential limitations in detecting targetable mutations.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.

Data from the phase 3 KEYNOTE-091 trial supported the European Commission’s approval of pembrolizumab as an adjuvant treatment for adults with non–small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discuss the importance of early dermatological consultations and multidisciplinary education for managing infusion-related adverse events like rashes from amivantamab, emphasizing the benefits of a well-coordinated team and the value of experience in responding to reactions.

Kristen Neumann, DNP, FNP-C, emphasizes the efficacy of the drug amivantamab for patients with EGFR exon 20 mutations, explaining the challenges of unique skin rashes, but highlighting the importance of teamwork in effectively managing and treating these adverse skin effects.

Findings from the phase 3 TARGET-TP trial support a biomarker-driven primary thromboprophylaxis strategy in adult patients with lung and gastrointestinal cancers as routine care.

Kristen Neumann, DNP, FNP-C, highlights the value of a multidisciplinary approach in the care of patients with EGFR-mutated non-small cell lung cancer, emphasizing the roles of dermatologists, pharmacists, and nurses in ensuring thorough patient assessment and education; Misako Nagasaka, MD, PhD, highlights data from WCLC 2023 on osimertinib in EGFR-mutated NSCLC.